(19)
(11) EP 1 635 875 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.12.2008 Bulletin 2008/52

(45) Mention of the grant of the patent:
08.10.2008 Bulletin 2008/41

(21) Application number: 04756068.5

(22) Date of filing: 25.06.2004
(51) International Patent Classification (IPC): 
A61K 47/34(2006.01)
(86) International application number:
PCT/US2004/020369
(87) International publication number:
WO 2005/002625 (13.01.2005 Gazette 2005/02)

(54)

IN-SITU GELLING DRUG DELIVERY SYSTEM

IN-SITU GELIERENDES ARZNEIMITTELABGABESYSTEM

PROCEDE DE LIBERATION DE MEDICAMENT A GELIFICATION IN-SITU

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 26.06.2003 US 482677 P
28.05.2004 US 575307 P

(43) Date of publication of application:
22.03.2006 Bulletin 2006/12

(60) Divisional application:
08017574.8

(73) Proprietor: pSivida Inc.
Watertown, MA 02472 (US)

(72) Inventors:
  • ASHTON, Paul
    Boston, MA 02108-1025 (US)
  • CHEN, Jianbing
    Belmont, MA 02478-4628 (US)
  • SU, Dongling
    Franklin, MA 02038 (US)

(74) Representative: Vossius & Partner 
Siebertstrasse 4
81675 München
81675 München (DE)


(56) References cited: : 
WO-A-02/00137
WO-A-02/45689
WO-A-97/26015
 WO-A-02/36169
WO-A-02/49573
US-A1- 2003 082 234
   
  • JAIN R A ET AL: "CONTROLLED DELIVERY OF DRUGS FROM A NOVEL INJECTABLE IN SITU FORMED BIODEGRADABLE PLGA MICROSPHERE SYSTEM" JOURNAL OF MICROENCAPSULATION, TAYLOR AND FRANCIS INC. LONDON, GB, vol. 17, no. 3, May 2000 (2000-05), pages 343-362, XP000912452 ISSN: 0265-2048
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).